Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology

American Journal of Clinical Oncology
Francesco PasqualettiFabiola Paiar

Abstract

Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite the large number of studies carried out in patients with recurrent GBM, little is known about the administration of this angiogenesis inhibitor after the failure of the second-line chemotherapy. In this retrospective multicenter study, on behalf of the Italian Association of Neuro-Oncology, we reported the results obtained in 51 patients with recurrent GBM treated with single-agent bevacizumab after the failure of second-line chemotherapy with fotemustine. In March 2016, at the time of data analysis, 3 patients (14.4%) were still alive with stable disease, whereas 48 died due to disease progression. Kaplan-Meier estimated median survival from the diagnosis of GBM was 28 months (95% confidence interval [CI], 22.1-33.9 mo). Median survival measured from the beginning of fotemustine and bevacizumab therapy were 11.3 (95% CI, 8.4-13.6 mo) and 6 months (95% CI, 3.8-8.1 mo), respectively. The 6- and 12-month progression free survival rates from the beginning of bevacizumab treatment were 18% and 13%, respectively. On the basis of our data, in patients with recurrent GBM, the failure of a second-line chemot...Continue Reading

References

Sep 1, 1996·Molecular and Cellular Biology·J A ForsytheG L Semenza
Jun 5, 2003·Journal of Neuro-oncology·Andrea SalmaggiAmerigo Boiardi
Jun 5, 2003·Nature Reviews. Cancer·Gabriele Bergers, Laura E Benjamin
Aug 7, 2003·Seminars in Radiation Oncology·Andy TrottiPhilip Rubin
Feb 3, 2005·JAMA : the Journal of the American Medical Association·Susan M ChangUNKNOWN Glioma Outcomes Project Investigators
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 16, 2005·Neuro-oncology·Balveen KaurErwin G Van Meir
Jul 24, 2007·Nature Reviews. Neuroscience·Rakesh K JainTracy T Batchelor
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jan 27, 2009·International Journal of Radiation Oncology, Biology, Physics·Philip H GutinLauren E Abrey
Jul 14, 2009·Journal of Neuro-oncology·Marc C Chamberlain, Sandra K Johnston
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Aug 10, 2010·Journal of Neuro-oncology·Raffaele AddeoSalvatore Del Prete
Apr 6, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Eric T WongSteven Brem
Dec 29, 2011·Journal of Neuro-oncology·Samuel A GoldlustAndrew B Lassman
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick
Mar 21, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Yasushi SodaInder M Verma
Jul 31, 2013·The Lancet Oncology·Michael WellerRoger Stupp
May 8, 2014·Journal of Neuro-oncology·Mohamed A HamzaJohn F DeGroot
Nov 16, 2016·Journal of Neuro-oncology·Paolo PerriniLodovico Lutzemberger

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.